(Circulation. 1995;92:1074-1078.)
© 1995 American Heart Association, Inc.
Articles |
Nifedipine in Ischemic Heart Disease
Correspondence to Robert A. Kloner, MD, PhD, The Heart Institute, Good Samaritan Hospital, 1225 Wilshire Blvd, Los Angeles, CA 90017.
Key Words: editorials • heart diseases • nifedipine • angina
 |
Introduction |
|---|
Until the 1980s, Prinzmetal's variant angina was difficult to treat—nitrates and ß-blockers usually did not control symptoms or signs of ischemia. In 1980, Antman et al1 reported the first clinical experience in the United States of the use of nifedipine in patients with Prinzmetal's angina. They used nifedipine capsules to treat 127 patients with Prinzmetal's angina, which reduced the weekly occurrences of angina from 16 to 2, reduced nitroglycerin requirements, completely controlled angina in 63% of patients, and reduced the frequency of angina by at least 50% in 87% of cases. Since that time, a number of trials with different calcium channel blockers, including nifedipine, diltiazem, verapamil, amlodipine, and others, have consistently shown that these agents are efficacious in reducing the morbidity of Prinzmetal's variant angina.2
Additional studies showed that calcium channel blockers, including nifedipine, were effective in patients with chronic stable angina pectoris3 ; they not only reduced symptoms but also reduced objective evidence of ischemia on exercise treadmill tests,4 5 reduced ST-segment changes on ambulatory ECG monitoring,6 increased coronary artery blood flow,7 8 9 and improved ventricular dysfunction associated with ischemia.10 Numerous studies showed that the calcium channel blockers were effective as antihypertensive agents and lacked many of the side effects of diuretics and ß-blockers.11
Of course, all drugs have limits, and not all
cardiovascular drugs are appropriate for all
cardiovascular situations. Calcium channel blockers are
no exception. In 1984, Muller et al11 showed for the first
time that nifedipine capsules did not reduce the size of
myocardial infarction (MI) and
This article has been cited by other articles:
 |
|
 |
|
  J. G. Jollis, R. J. Simpson Jr, M. K. Chowdhury, W. E. Cascio, J. R. Crouse III, M. W. Massing, and S. C. Smith Jr Calcium Channel Blockers and Mortality in Elderly Patients With Myocardial Infarction Arch Intern Med, October 25, 1999; 159(19): 2341 - 2348. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. J. Pepine, E. Handberg-Thurmond, R. G. Marks, M. Conlon, R. Cooper-Dehoff, P. Volkers, P. Zellig, and for The INVEST Investigators Rationale and design of the International Verapamil SR/Trandolapril Study (INVEST): an Internet-based randomized trial in coronary artery disease patients with hypertension J. Am. Coll. Cardiol., November 1, 1998; 32(5): 1228 - 1237. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. M. Abascal, M. G. Larson, J. C. Evans, A. T. Blohm, K. Poli, and D. Levy Calcium Antagonists and Mortality Risk in Men and Women With Hypertension in the Framingham Heart Study Arch Intern Med, September 28, 1998; 158(17): 1882 - 1886. [Abstract] [Full Text]
|
|
|
|
 |
|
 H. T. Stelfox, G. Chua, K. O'Rourke, and A. S. Detsky Conflict of Interest in the Debate over Calcium-Channel Antagonists N. Engl. J. Med., January 8, 1998; 338(2): 101 - 106. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Ishikawa, S. Nakai, T. Takenaka, K. Kanamasa, J. Hama, I. Ogawa, T. Yamamoto, M. Oyaizu, A. Kimura, K. Yamamoto, et al. Short-Acting Nifedipine and Diltiazem Do Not Reduce the Incidence of Cardiac Events in Patients With Healed Myocardial Infarction Circulation, May 20, 1997; 95(10): 2368 - 2373. [Abstract] [Full Text]
|
|
|
|
|
|
T. C. Fagan Calcium Antagonists and Mortality: Another Case of the Need for Clinical Judgment Arch Intern Med, November 13, 1995; 155(20): 2145 - 2145. [Abstract] [PDF]
|
|
|
|
|
|
M. Epstein Calcium Antagonists Should Continue to Be Used for First-Line Treatment of Hypertension Arch Intern Med, November 13, 1995; 155(20): 2150 - 2156. [Abstract] [PDF]
|
|